GSS
vs
S
S&P/ASX 300

Over the past 12 months, GSS has underperformed S&P/ASX 300, delivering a return of -56% compared to the S&P/ASX 300's +12% growth.
Stocks Performance
GSS vs S&P/ASX 300
Performance Gap
GSS vs S&P/ASX 300
Performance By Year
GSS vs S&P/ASX 300
Genetic Signatures Ltd
Glance View
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.
